Beneficial effects of bardoxolone methyl, an Nrf2 activator, on crush-related acute kidney injury in rats
- 107 Downloads
The purpose of this study was to investigate the effects of bardoxolone methyl (BM), a nuclear factor erythroid 2-related factor 2 (Nrf2) activator, on acute kidney injury in a rat model of crush syndrome model.
Sixty-four rats were separated equally into eight groups, sham (sterile saline ip), crush, crush + vehicle (DMSO ip), and crush + BM (10 mg/kg ip) (n = 8). All groups were also divided as 3 and 24 h after decompression. Crush injury was induced by 6 h of direct compression to both hind limbs of the rats with blocks weighing 3.6 kg on each side, followed by 3 and 24 h of decompression. Kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), tumor necrotizing factor-α (TNF-α), transforming growth factor-β1 (TGF-β1) concentrations, tissue total oxidant status (TOS) and total antioxidant status (TAS) were measured in the kidneys. Serum creatine kinase (CK), blood urea nitrogen (BUN) and creatinine concentrations were also measured. Glomerular and tubular structures were examined histopathologically. Bcl-2 was measured using immunohistochemistry. Apoptosis was assessed using the TUNEL method.
BM treatment reduced KIM-1, NGAL, TNF-α, TGF-β1, TOS concentrations, and increased TAS concentrations in the kidneys 3 and 24 h after decompression. Serum CK, BUN and creatinine concentrations were also reduced with BM. BM treatment decreased apoptosis in crush-related AKI. The Nrf2 activator BM reversed the crush-induced changes in the experimental rats.
BM treatment prevented the progression of crush-related AKI in rats possibly through its cytoprotective effects of being an antioxidant, anti-inflammatory and anti-apoptotic agent.
KeywordsCrush syndrome Bardoxolone methyl Acute kidney injury Nrf2
This research was supported by Dumlupınar University Scientific Research Projects Unit, Kütahya, Turkey (Project no. 2016-16).
Study design: EK and YT. Animal studies and ELISA measurements: FEK and YT. Histopathologic examinations: CK. Biochemical measurement and interpretation: FEK. Manuscript writing and preparation of figures: YT and EK.
Compliance with ethical standards
Conflict of interest
The authors declare that there are no conflicts of interest.
The experimental protocol was approved by the animal ethical committee of Dumlupınar University (Approval no. 2015.11.02).
- 1.Sever MS, Vanholder R, Ashkenazi I, Becker G, Better O, Covic A, De Smet M, Eckardt KU, Eknoyan G, Gibney N, Hoste E, Kazancioglu R, Lameire N, Luyckx V, Portilla D, Tuglular S, Van Biesen W. Recommendation for the management of crush victims in mass disasters. Nephrol Dial Transpl. 2012;27(Suppl 1):i1–67.CrossRefGoogle Scholar
- 3.Murata I, Ooi K, Shoji S, Motohashi Y, Kan M, Ohtake K, Kimura S, Ueda H, Nakano G, Sonoda K, Inoue Y, Uchida H, Kanamoto I, Morimoto Y, Kobayashi J. Acute lethal crush-injured rats can be successfully rescued by a single injection of high-dose dexamethasone through a pathway involving PI3K-Akt-eNOS signaling. J Trauma Acute Care Surg. 2013;75:241–9.CrossRefPubMedGoogle Scholar
- 4.Murata I, Nozaki R, Ooi K, Ohtake K, Kimura S, Ueda H, Nakano G, Sonoda K, Inoue Y, Uchida H, Kanamoto I, Morimoto Y, Kobayashi J. Nitrite reduces ischemia/reperfusion-induced muscle damage and improves survival rates in rat crush injury model. J Trauma Acute Care Surg. 2012;72(6):1548–54.CrossRefPubMedGoogle Scholar
- 8.Lambers Heerspink HJ, Chertow GM, Akizawa T, Audhya P. Baseline characteristics in the bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes mellitus: the occurrence of renal events (BEACON) trial. Nephrol Dial Transplant. 2013;28(11):2841–50.CrossRefPubMedGoogle Scholar
- 14.de Zeeuw D, Akizawa T, Audhya P, Bakris GL, Chin M, Christ-Schmidt H, Goldsberry A, Houser M, Krauth M, Lambers Heerspink HJ, McMurray JJ, Meyer CJ, Parving HH, Remuzzi G, Toto RD, Vaziri ND, Wanner C, Wittes J, Wrolstad D, Chertow GM, BEACON Trial Investigators. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013;369:2492–503.CrossRefPubMedPubMedCentralGoogle Scholar
- 15.Chin MP, Bakris GL, Block GA, Chertow GM, Goldsberry A, Inker LA, Heerspink HJL, O'Grady M, Pergola PE, Wanner C, Warnock DG, Meyer CJ. Bardoxolone methyl improves kidney function in patients with chronic kidney disease stage 4 and type 2 diabetes: post-hoc analyses from bardoxolone methyl evaluation in patients with chronic kidney disease and type 2 diabetes study. Am J Nephrol. 2018;47(1):40–7.CrossRefPubMedPubMedCentralGoogle Scholar
- 16.Wu QQ, Wang Y, Senitko M, Meyer C, Wigley WC, Ferguson DA, Grossman E, Chen J, Zhou XJ, Hartono J, Winterberg P, Chen B, Agarwal A, Lu CY. Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1. Am J Physiol Renal Physiol. 2011;300:F1180–F1192192.CrossRefPubMedPubMedCentralGoogle Scholar
- 18.Takikawa M, Nakamura S, Ishihara M, Takabayashi Y, Fujita M, Hattori H, Kushibiki T, Ishihara M. Improved angiogenesis and healing in crush syndrome by fibroblast growth factor-2-containing low-molecular-weight heparin (Fragmin)/protamine nanoparticles. J Surg Res. 2015;196(2):247–57.CrossRefPubMedGoogle Scholar
- 19.Yates MS, Tauchi M, Katsuoka F, Flanders KC, Liby KT, Honda T, Gribble GW, Johnson DA, Johnson JA, Burton NC, Guilarte TR, Yamamoto M, Sporn MB, Kensler TW. Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulatedgenes. Mol Cancer Ther. 2007;6:154–62.CrossRefPubMedGoogle Scholar
- 20.Bubb KJ, Kok C, Tang O, Rasko NB, Birgisdottir AB, Hansen T, Ritchie R, Bhindi R, Reisman SA, Meyer C, Ward K, Karimi Galougahi K, Figtree GA. The NRF2 activator DH404 attenuates adverse ventricular remodeling post-myocardial infarction by modifying redox signalling. Free Radic Biol Med. 2017;108:585–94.CrossRefPubMedGoogle Scholar
- 28.Murata I, Ooi K, Sasaki H, Kimura S, Ohtake K, Ueda H, Uchida H, Yasui N, Tsutsui Y, Yoshizawa N, Hirotsu I, Morimoto Y, Kobayashi J. Characterization of systemic and histologic injury after crush syndrome and intervals of reperfusion in a small animal model. J Trauma. 2011;70(6):1453–63.CrossRefPubMedGoogle Scholar
- 34.Ding Y, Stidham RD, Bumeister R, Trevino I, Winters A, Sprouse M, Ding M, Ferguson DA, Meyer CJ, Wigley WC, Ma R. The synthetic triterpenoid, RTA 405, increases the glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells. Kidney Int. 2013;83(5):845–54.CrossRefPubMedGoogle Scholar
- 38.Thimmulappa RK, Fuchs RJ, Malhotra D, Scollick C, Traore K, Bream JH, Trush MA, Liby KT, Sporn MB, Kensler TW, et al. Preclinical evaluation of targeting the Nrf2 pathway by triterpenoids (CDDO-Im and CDDO-Me) for protection from LPS-induced inflammatory response and reactive oxygen species in human peripheral blood mononuclear cells and neutrophils. Antioxid Redox Signal. 2007;9:1963–70.CrossRefPubMedPubMedCentralGoogle Scholar